Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents

Published:2017-09-26 Issue:10 Volume:46 Page:992-1000
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Lin M.¹^ORCID,Kramer J.²³^ORCID,White D.²³,Cao Y.²³,Tavakoli-Tabasi S.⁴,Madu S.¹,Smith D.¹²,Asch S. M.⁵⁶,El-Serag H. B.¹²³,Kanwal F.¹²³

Affiliation:

1. Department of Gastroenterology and Hepatology; Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine; Houston TX USA

2. Center of Innovation, Effectiveness and Quality; Michael E. DeBakey Veterans Affairs Medical Center; Houston TX USA

3. Sections of Health Services Research; Baylor College of Medicine; Houston TX USA

4. Department of Infectious Diseases; Michael E. DeBakey Veterans Affairs Medical Center; Baylor College of Medicine; Houston TX USA

5. Center for Innovation to Implementation (Ci2i); Palo Alto Veterans Affairs Medical Center; Palo Alto CA USA

6. Division of General Medical Disciplines; Stanford University; Palo Alto CA USA

Funder

Health Services Research and Development

Veterans Administration Center for Innovations in Quality, Effectiveness and Safety

Michael E. DeBakey VA Medical Center

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14328/fullpdf

Reference17 articles.

1. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection;Foster;N Engl J Med,2015

2. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis;Kowdley;N Engl J Med,2014

3. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study;Nelson;Hepatology,2015

4. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System;Ioannou;Gastroenterology,2016

5. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients;Backus;Hepatology,2016

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Initiation of oral hepatitis C virus treatment: Which barriers are pertinent for ambulatory individuals with a history of illicit substance use? A qualitative interview study;Health Science Reports;2024-01

2. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals;Drug and Alcohol Dependence;2023-12

3. Cross‐sectional HIV and HCV cascades of care across the regions of Ukraine between 2019 and 2020: findings from the CARE cohort;Journal of the International AIDS Society;2023-09

4. Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD;Journal of Viral Hepatitis;2023-06-29

5. Characteristics associated with receipt of treatment among patients diagnosed with chronic hepatitis C virus;Journal of Viral Hepatitis;2023-06-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3